Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study

Article Oncology

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Zev A. Wainberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Meeting Abstract Oncology

Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemoradiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1-NK cell therapy

Tara Elisabeth Seery et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin

Tai-Jan Chiu et al.

Summary: This study investigated the effect of previous conventional irinotecan treatment on the efficacy of nal-IRI+5-FU/LV treatment in mPDAC patients. The results showed that previous conventional irinotecan treatment does not compromise the survival time and tumor response rate of subsequent nal-IRI+5-FU/LV treatment in patients.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2022)

添加到收藏夹

Article Medicine, General & Internal

Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma

George Kim et al.

Summary: This study evaluated the occurrence of chemotherapy-related adverse events (AEs) and the use of medications in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy. The results showed that patients receiving liposomal irinotecan-based regimens had lower rates of AEs and required lower levels of medication compared to other regimens.

CURRENT MEDICAL RESEARCH AND OPINION (2022)

添加到收藏夹

Article Oncology

Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer br

Tomohisa Otsu et al.

Summary: This study compared the efficacy of second-line FOLFIRINOX and nal-IRI/FL treatment in patients with pancreatic ductal adenocarcinoma after first-line GnP therapy. The results showed similar progression-free survival and overall survival between the two treatment groups, but FOLFIRINOX required more supportive treatment and dose reduction.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study

Shun Tezuka et al.

Summary: This study compared the efficacy and safety of three different chemotherapy regimens for unresectable pancreatic cancer. The results showed that the modified FOLFIRINOX group and FOLFIRI group had longer overall survival, and the FOLFIRI group had a lower incidence of treatment-related adverse events. Therefore, modified FOLFIRINOX, FOLFIRI, and nal-IRI/5-FU/LV can all be considered as treatment options for second-line chemotherapy for unresectable pancreatic cancer.

PANCREATOLOGY (2022)

添加到收藏夹

Article Oncology

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

Takuo Yamai et al.

Summary: Salvage chemotherapy for patients with unresectable pancreatic cancer who were previously treated with gemcitabine, nab-paclitaxel, 5-fluorouracil, leucovorin, and nanoliposomal irinotecan has not been fully established. This retrospective study found that the FOLFOX regimen may have limited benefits for these patients, particularly those with homologous recombination deficiency-associated gene mutations.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)

H. S. Park et al.

Summary: This retrospective study evaluated the clinical outcomes of second-line treatments in patients with metastatic pancreatic cancer, finding that liposomal irinotecan plus fluorouracil/ leucovorin (nal-IRI/FL) and FOLFIRINOX showed similar effectiveness outcomes after progression following first-line gemcitabine-based therapy. The study suggests that age could be a determining factor for choosing the appropriate second-line therapy.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience

Anup Kasi et al.

Summary: The study found that nano-liposomal irinotecan combined with 5-fluorouracil/leucovorin as an advanced line of treatment in patients with advanced pancreatic cancer provides some survival benefits and safety. The treatment response to this regimen is somewhat correlated with the previous treatment regimens that patients have received, but there was no significant difference in survival outcomes for patients given this regimen as either the first or beyond the second line of treatment.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer

Neslihan Kayahan et al.

Summary: This study compared the efficacy and safety of FOLFIRINOX and gemcitabine-cisplatin as first-line therapy in pancreatic cancer patients. It found that FOLFIRINOX showed significant advantages in overall survival and progression-free survival compared to gemcitabine-cisplatin for patients with good performance status.

TURKISH JOURNAL OF MEDICAL SCIENCES (2021)

添加到收藏夹

Article Oncology

Pancreatic Adenocarcinoma, Version 2.2021

Margaret A. Tempero et al.

Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with a major challenge being advanced disease at diagnosis. While survival rates have not significantly changed, newer treatments, including targeted therapies, offer hope for patients. The manuscript focuses on systemic therapy approaches for locally advanced and metastatic disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Oncology

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy

Kyunghye Bang et al.

Summary: The study demonstrated that nal-IRI plus 5-FU/LV showed modest efficacy and manageable toxicities in patients with mPAC previously treated with conventional irinotecan-containing chemotherapy. The cumulative dose of prior conventional irinotecan therapy may be inversely correlated with the effectiveness of nal-IRI plus 5-FU/LV.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy